Altos Labs Stock

altoslabs.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $11.13B

Altos Labs is an American biotechnology research company founded in 2022 and focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. Altos has operations in San Francisco, San Diego, and in Cambridge, UK, with significant collaborations in Japan, with a Board of Directors and advisors including Nobel Laureates and scientific leaders.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Altos Labs, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Altos Labs Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Altos Labs Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
02/14/2024 Series C $1.5B $xx.xx $6.33B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
59,781,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/25/2022 Series B $818.78MM $xx.xx $3.67B Arch Venture Partners, Mubadala Investment Company
Price per Share
$xx.xx
Shares Outstanding
42,759,506
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Mubadala Investment Company
09/04/2021 Series A $305.91MM $xx.xx $1.33B Jeff Bezos, Yuri Milner
Price per Share
$xx.xx
Shares Outstanding
34,102,438
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Jeff Bezos, Yuri Milner

Altos Labs Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Hans Bishop
Co-Founder & President
Ann Lee-Karlon Ph.D
Chief Operating Officer
Hal Barron MD
Chief Executive Officer
Richard Klausner MD
Co-Founder & Chief Scientist

Altos Labs stock FAQs

plusminus

Can you buy Altos Labs stock?

As Altos Labs is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Altos Labs, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Altos Labs stock?

To invest in a private company like Altos Labs through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Altos Labs stock?

Yes, you may sell the Altos Labs stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Altos Labs stock?

If you hold private company shares of Altos Labs – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Altos Labs on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Altos Labs a public company?

No, Altos Labs is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Altos Labs’ stock price?

Altos Labs is a privately held company and therefore does not have a public stock price. However, you may access Altos Labs private market stock price with Forge Data.
plusminus

What is Altos Labs’ stock ticker symbol?

Altos Labs does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Altos Labs News and Media Highlights

For This Venture Capitalist, Research on Aging Is Personal; ‘Bob Has a Big Fear of Death’

The investment firm Robert Nelsen co-founded in 1986, Arch Venture Partners, has racked up billions in profits from early stakes in companies developing methods to detect and treat cancer and other diseases. In his personal life, Nelsen, 60 years old, downs a daily cocktail of almost a dozen different drugs, including rapamycin, metformin, taurine and nicotinamide mononucleotide, all of which he says help prevent illness and promote longevity. Nelsen has a full-body MRI every six months, sees a dermatologist every three months and has annual blood tests to detect cancer. At his home in the Rocky Mountains, he works out in an “electric suit” that he says emits low-frequency impulses to build muscle and improve health.

Altos Labs Announces Sponsored Research Agreement with Kyoto University's CiRA to Foster Cellular Rejuvenation Programming Research

Altos Labs (Altos) today announced that it has signed a sponsored research agreement with the Center for iPS Cell Research and Application (CiRA) at Japan's Kyoto University. Effective May 1 of this year, Altos has committed to fund four CiRA research projects for five years to investigate aspects of cellular rejuvenation programming. Under the sponsored research agreement, projects are supervised by Altos Senior Scientific Advisor Shinya Yamanaka, who is also Professor and Director Emeritus at CiRA. He does not receive any remuneration from Altos.

Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease

Altos Labs just redefined big in biotech. Where to start? The $3 billion in investor support? The C-suite staffed by storied leaders—Barron, Bishop, Klausner—identifiable by one name? Or the wildly ambitious plan to reverse disease for patients of any age? Altos is all that and more. Early details of Altos leaked out last year when MIT Technology Review reported Jeff Bezos had invested to support development of technology that could “revitalize entire animal bodies, ultimately prolonging human life.” The official reveal fleshes out the vision and grounds the technology in the context of the nearer-term opportunities it presents to improve human health.

Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming

Altos Labs™ (Altos™) launched today as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission.
Browse Insights
Updated on: Dec 11, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.